Impact of phosphatidylethanol in the surveillance for alcohol use in post-liver transplant population: A retrospective study

Sergio A De La Torre; Brittney Ibrahim; Katherine Meneses; Sammy Saab; Akshay Shetty

doi:10.1111/acer.15474

Impact of phosphatidylethanol in the surveillance for alcohol use in post-liver transplant population: A retrospective study

Alcohol Clin Exp Res (Hoboken). 2024 Oct 31. doi: 10.1111/acer.15474. Online ahead of print.

Authors

Sergio A De La Torre¹, Brittney Ibrahim^{1

2}, Katherine Meneses², Sammy Saab^{1

2}, Akshay Shetty^{1

2}

Affiliations

¹ Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
² Department of Surgery, University of California at Los Angeles, Los Angeles, California, USA.

PMID: 39482857
DOI: 10.1111/acer.15474

Abstract

Background: Alcohol-related liver disease (ALD) is the leading indication for liver transplantation in the United States. The aim of this study was to describe the impact of phosphatidylethanol (PEth) in the surveillance for alcohol use after liver transplantation.

Methods: We conducted a single-center retrospective study to assess the impact of phosphatidylethanol (PEth) for the surveillance of alcohol use and its correlation to health outcomes. We compared orthotopic liver transplant (OLT) recipients for ALD transplanted between 2016 and 2018, before the introduction of PEth, to those transplanted between 2019 and 2022, after the introduction of PEth. Alcohol relapse versus nonrelapse cohorts were also compared. Follow-up time for all cohorts was limited to 3 years post-OLT. Continuous variables were analyzed with an independent t-test and categorical variables with Fischer's exact test and chi-square test. The Kaplan-Meier method and log-rank test were used to assess alcohol-free survival.

Results: We reviewed 263 patients who were transplanted for ALD; 46 (17.5%) patients were noted to have at least one episode of alcohol relapse after their transplant. Patients with alcohol relapse had more frequent episodes of elevated liver enzymes compared with nonrelapsed patients (4.35 episodes vs. 2.46 episodes respectively, p < 0.001). The number of hospitalizations was also noted to be elevated among relapsed versus nonrelapsed patients; however, this was not statistically significant (2.85 vs. 2.50 respectively, p = 0.307). When comparing relapse rates before and after the introduction of PEth, relapses were notably detected more frequently after the introduction of PEth (17% vs. 7%, p = 0.012). No difference was noted in rates of mortality between patients who did or did not relapse.

Conclusions: Overall, PEth is an effective surveillance tool in the postliver transplant population to monitor for alcohol relapse. Early detection of relapse can lead to opportunities for early intervention to avoid alcohol-related complications.

Keywords: PEth; alcohol relapse; alcohol‐related liver disease; liver transplant; phosphatidylethanol.